May 09, 2017 7:00am EDT Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
Dec 16, 2016 9:27am EST Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock